HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.

AuthorsGraham P Collins, Toby A Eyre, Kim M Linton, John Radford, Grant D Vallance, Elizabeth Soilleux, Chris Hatton
JournalBritish journal of haematology (Br J Haematol) Vol. 170 Issue 6 Pg. 886-90 (Sep 2015) ISSN: 1365-2141 [Electronic] England
PMID25721307 (Publication Type: Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
  • Antineoplastic Agents
  • Organophosphates
  • Protein Kinase Inhibitors
  • Quinazolines
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, pathology)
  • Male
  • Middle Aged
  • Organophosphates (administration & dosage, adverse effects, therapeutic use)
  • Protein Kinase Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Quinazolines (administration & dosage, adverse effects, therapeutic use)
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: